Sophia Genetics SA

SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. It operates through the following geographical segments: France, Italy, United States, Spain, Turkey, Austria, Brazil, United Kingdom, Switzerland, Germany, and Other. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SOPHiA GENETICS excels in Q4 2022, eyes biopharma growth

SOPHiA GENETICS reported strong financial performance in Q4 2022 and full-year 2022, driven by revenue growth, strategic partnerships, and operational efficiency improvements.
The company's focus on oncology and rare diseases, along with its multimodal approach and commitment to customer satisfaction, positions it well for sustained growth and value creation.
While facing challenges in maintaining growth momentum and managing operational metrics, SOPHiA has significant opportunities for expansion, partnerships, and leveraging AI for platform enhancement.

Sophia Genetics reports strong Q1 performance and eyes pharma growth

Sophia Genetics delivered strong Q1 results with revenue growth and customer expansions.
The company's focus on innovation and strategic partnerships positions it well for future growth.
While facing macro challenges and seasonal variability, Sophia Genetics remains optimistic about revenue growth.
Pharma partnerships and global presence offer significant growth opportunities for the company.

Sophia Genetics reports robust Q2 growth and strategic partnerships

Sophia Genetics delivered strong Q2 results with revenue growth and improved operating loss, driven by customer expansion and high growth areas like HRD testing and liquid biopsy.
While facing financial challenges, the company is actively managing costs and pursuing opportunities in innovative initiatives like DEEP-Lung-IV and MRD testing applications.
With a focus on sustaining growth and profitability, Sophia Genetics aims to leverage its strengths in genomics analytics and strategic partnerships to capitalize on market opportunities.
Investor confidence is reinforced by the company's reiterated annual guidance and expectations of continued growth, positioning Sophia Genetics for future success.

Sophia Genetics reports strong Q3 growth and strategic partnerships

Sophia Genetics delivered robust Q3 results, showing growth in revenue, customer adoption, and strategic partnerships.
Despite challenges in operating losses and lack of 2024 guidance, the company remains focused on sustainable growth and profitability.
Opportunities in precision medicine applications, FDA oversight alignment, and strong sales metrics position Sophia Genetics for continued success.

SOPHiA GENETICS reports strong Q4 earnings, eyes global expansion

SOPHiA GENETICS showcased robust financial performance, operational efficiency, and strategic growth initiatives in Q4 2023.
The company's focus on innovation, global expansion, and customer acquisition positions it well for future growth and market leadership.
Challenges in financial management and technology adaptation require careful navigation for sustained profitability and market competitiveness.
Opportunities in product expansion, market penetration, and strategic partnerships offer avenues for continued revenue growth and market expansion.

SOPHiA GENETICS reports solid Q1 performance and strategic growth plans

SOPHiA GENETICS reported solid Q1 performance with revenue growth to $15.8 million, strong bookings, and new logos signed.
Despite challenges in setup times and biopharma delays impacting revenue slightly, the company maintains full-year revenue guidance and operational targets.
Opportunities lie in emerging sequencing platforms adoption, new clinical business bookings, and potential acquisitions for growth and market leadership.
Overall, SOPHiA's strategic actions, competitive strengths, and commitment to sustainable growth position the company for continued success and expansion.

SOPHiA Genetics addresses revenue challenges, eyes growth opportunities in genomics

SOPHiA Genetics navigated challenges in Q2 with a focus on strategic actions and new opportunities. Despite revenue setbacks, the company is optimistic about future growth drivers and market initiatives. The revised full-year revenue outlook reflects a commitment to cost management and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Launch of new application enables global access to highly recognized solid tumor profiling assay BOSTON and ROLLE, Switzerland , Nov. 21, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, announced the global launch of MSK-IMPACT® powered with SOPHiA DDM™ today from the Association for Molecular Pathology (AMP) Annual Meeting. This innovative solution provides organizations worldwide with the opportunity to benefit from Memorial Sloan Kettering Cancer Center (MSK)'s best-in-class comprehensive genomic profiling (CGP) application on the SOPHiA DDM™ Platform with high accuracy and efficiency.

SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024

SOPHiA GENETICS SA (NASDAQ:SOPH ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Kellen Sanger - Head of Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer George Cardoza - Incoming Chief Financial Officer Ross Muken - Executive Vice President, Chief Financial Officer & Chief Operating Officer Conference Call Participants Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Conor McNamara - RBC Capital Markets Operator Good morning. My name is Nicole [ph] and I will be your conference operator today.

SOPHiA GENETICS SA (SOPH) Q3 2024 Earnings Call Transcript

BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO.

SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer

Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2024. Third Quarter  2024 Financial Results Revenue was $15.9 million, down 2.8% year-over-year Gross margins were 67.2% on a reported basis and 73.1% on an adjusted basis, compared to 69.1% and 72.5% in the prior year period, respectively Operating loss was $15.4 million on a reported basis and $10.6 million on an adjusted basis, representing year-over-year improvements of 7.1% and 10.4%, respectively Cash burn was $9.6 million, representing a year-over-year improvement of 39.1% The company reiterates full-year guidance, including revenue between $65 million and $67 million, adjusted gross margin of 72.0% to 72.5%, and adjusted operating loss between $45 million and $50 million "Record analysis volume drove a reacceleration of Clinical growth across most key geographies in Q3, with volume increasing 16% year-over-year, offset by expected softness in BioPharma," said Jurgi Camblong, PhD.

SOPHiA GENETICS Reports Third Quarter 2024 Results

BOSTON and ROLLE, Switzerland , Oct. 22, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal year 2024 before U.S. markets open on Tuesday, November 5, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.

SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy BOSTON and ROLLE, Switzerland , Sept. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024.

SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being held in Barcelona, Spain September 13-17, 2024.

SOPHiA GENETICS Announces Poster Presentations at ESMO 2024

The global collective intelligence network aims to accelerate precision oncology research and care BOSTON and ROLLE, Switzerland , Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update that several world-renowned healthcare organizations have joined SOPHiA UNITY.

SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024

AstraZeneca

The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months BOSTON and ROLLE, Switzerland , Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023.

SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio BOSTON and ROLLE, Switzerland , Sept. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company's work with biopharma company Boundless Bio.

SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

New generation of SOPHiA DDM TM  integrates latest  advancements in data processing and technology to deliver elevated experience and capabilities to customers BOSTON and ROLLE, Switzerland , Sept. 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today launched the new generation of the SOPHiA DDMTM Platform.

SOPHiA GENETICS Unveils New Generation of the SOPHiA DDMTM Platform at Morgan Stanley Healthcare Conference 2024

BOSTON and ROLLE, Switzerland , Aug. 28, 2024 /PRNewswire/ -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced presentations at the 22nd Annual Morgan Stanley Healthcare Conference and the 9th Annual TD Cowen FutureHealth Conference in early September. Chief Financial Officer and Chief Operating Officer, Ross Muken, will present at the 22nd Annual Morgan Stanley Healthcare Conference in New York City on Wednesday, September 4, 2024, at 1:50 p.m.

SOPHiA GENETICS to Present at the 22nd Annual Morgan Stanley Healthcare Conference and 9th Annual TD Cowen FutureHealth Conference

Regulatory milestone validates the SOPHiA DDM™ Platform as diagnostic tool in select markets BOSTON and ROLLE, Switzerland , Aug. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that its SOPHiA DDM™ Platform is now CE marked under the European Union's In Vitro Diagnostic Regulation (IVDR). IVDR certification is a significant regulatory milestone that validates the powerful analytical capabilities of the SOPHiA DDM™ Platform and allows customers throughout the European Union and other markets recognizing this certification to use the SOPHiA DDM™ Platform to support patient diagnostics.

SOPHiA DDM™ Platform Certified Under IVDR

The heavy selling pressure might have exhausted for SOPHiA GENETICS (SOPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

SOPHiA GENETICS (SOPH) Loses -30.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

SOPHiA GENETICS (SOPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes SOPHiA GENETICS (SOPH) a New Buy Stock

SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago.

SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates

Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management B uffers Loss BOSTON and ROLLE, Switzerland , Aug. 6, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2024. Second Quarter  2024 Financial Update Revenue was $15.8 million, up 5% year-over-year; Constant currency revenue excluding COVID-19 revenue was $16.0 million, up 7% year-over-year Gross margins were 68.2% on a reported basis and 73.2% on an adjusted basis, up from 66.7% and 70.0% in the prior year period, respectively Operating loss was $15.0 million on a reported basis and $9.9 million on an adjusted basis, representing year-over-year improvements of 25% and 32%, respectively 2024 Financial Outlook Full-year revenue is now expected to be between $65 million and $67 million, representing growth of 4% to 7% compared to FY 2023 Adjusted gross margin is now expected to be between 72.0% to 72.5%, compared to 72.2% in FY 2023 Adjusted operating loss guidance remains unchanged and is expected to be between $45M and $50M, compared to $55.9 million in FY 2023 "We delivered another quarter of strong forward-looking indicators and continued bottom-line improvements in Q2, despite facing macro-related headwinds in BioPharma and EMEA which offset outsized performance in the U.S.," said Jurgi Camblong, PhD.

SOPHiA GENETICS Reports Second Quarter 2024 Results

The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland , July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that L'hôpital Universitaire Avicenne is implementing the SOPHiA DDM™ Platform. The hospital, located in Bobigny, France, will use the platform to advance its testing and research of blood-related cancers and disorders.

SOPHiA GENETICS Announces L'hôpital Universitaire Avicenne is Live on SOPHiA DDM™

OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland , July 24, 2024  /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that OncoHelix, an internationally recognized research and diagnostics laboratory for precision diagnostics, will implement MSK-ACCESS® powered with SOPHiA DDM™. The organization, which currently uses the SOPHiA DDM™ Platform for myeloid testing, will use the new liquid biopsy solution to advance its oncology testing capabilities.

SOPHIA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix

OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™ BOSTON and ROLLE, Switzerland , July 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that OncoHelix, an internationally recognized research and diagnostics laboratory for precision diagnostics, will implement MSK-ACCESS® powered with SOPHiA DDM™. The organization, which currently uses the SOPHiA DDM™ Platform for myeloid testing, will use the new liquid biopsy solution to advance its oncology testing capabilities.

SOPHiA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix

BOSTON and ROLLE, Switzerland , July 23, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the second quarter of fiscal year 2024 before U.S. markets open on Tuesday, August 6, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.

SOPHiA GENETICS to Announce Financial Results for Second Quarter 2024 on August 6, 2024

The diagnostics company has implemented the SOPHiA DDM™ Platform to enhance its solid tumor testing BOSTON and ROLLE, Switzerland , July 4, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA DDM™ Platform. The company will use SOPHiA GENETICS' technology to enhance its solid tumor testing capabilities.

India-Based Dhiti Omics is Now Live on SOPHiA DDM™

BOSTON and ROLLE, Switzerland, June 24, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a healthcare technology company and a leader in data-driven medicine, is pleased to announce that its annual general meeting of shareholders (the “AGM”) was held at the Company's headquarters, La Piece 12, 1180 Rolle/VD, Switzerland, earlier today at 14:00 CEST (8:00 a.m. EDT). The Company's shareholders have adopted all proposals presented at the AGM.

SOPHiA GENETICS Publishes Results of 2024 Annual General Meeting

Novel application supports measurable residual disease (MRD) testing to help monitor cancer and stay ahead of relapse BOSTON and ROLLE, Switzerland , June 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced its new Residual Acute Myeloid (RAM) Application. The new offering expands the company's comprehensive oncology portfolio to support measurable residual disease (MRD) capabilities and will be available to customers worldwide this summer.

SOPHiA GENETICS Launches New Residual Acute Myeloid (RAM) Application

The Hospital will use SOPHiA DDM™ to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland , June 13, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that Kepler Uniklinikum, Austria's second largest hospital, is live on SOPHiA GENETICS' platform. The hospital will use the SOPHiA DDM™ Platform to advance its next-generation sequencing (NGS) testing and diagnostics of blood-related cancers.

News for Sophia Genetics SA Stock (SOPH)